GPT and sclerosing cholangitis: In Phase 2 clinical trials, administration of norUDCA for 12 weeks reduced serum alkaline phosphatase (ALP) and other liver enzyme markers of cholestasis in patients with primary sclerosing cholangitis (PSC) (8), and it reduced serum alanine aminotransferase (ALT) in patients with nonalcoholic fatty liver disease (9).